Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer. The FDA has accepted a ...

The FDA has accepted the sBLA for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a potential first-line treatment for advanced MSI-H or dMMR CRC.

智通财经APP获悉，百时美施贵宝(BMY.US)宣布，欧盟委员会(EC)已批准其重磅PD-1抑制剂Opdivo(nivolumab)与CTLA-4靶向抗体Yervoy(ipilimumab)联用，一线治疗不可切除或晚期肝细胞癌(HCC)成人患者。据悉 ...

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy ...

The triplet regimen of cabozantinib, nivolumab, and ipilimumab improved PFS in aRCC patients but did not enhance OS compared to the doublet regimen. Patients receiving the triplet regimen experienced ...

(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the New Drug Application or NDA for ipilimumab injection (anti-CTLA-4 monoclonal antibody) has been accepted by the Center for Drug ...

百时美施贵宝（BMY.US）近日宣布，欧盟委员会已批准其新型免疫疗法Opdivo（nivolumab）与CTLA-4靶向抗体Yervoy（ipilimumab）组合用于治疗不可切除或晚期肝细胞癌（HCC）成人患者。此项治疗被认为具有重大意义，因它能显著延长患者的生存期，带来新的治疗希望。根据公司发布的数据，使用Opdivo联合Yervoy的患者中位生存期达到23.7个月，明显优于活性对照组的20.

US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus ...